|[March 19, 2014]
The Shuman Law Firm Investigates Galena Biopharma, Inc.
BOULDER, Colo. --(Business Wire)--
Shuman Law Firm announces that it is investigating potential claims
against certain officers and directors of Galena Biopharma, Inc.
("Galena" or the "Company") (Nasdaq: GALE).
Galena is an Oregon-based biopharmaceutical company commercializing and
developing innovative, targeted oncology treatments that address major
unmet medical needs to advance cancer care.
Firm's investigation relaes to allegations raised in a thestreet.com
exposé which suggested that Galena misrepresented and/or failed to
disclose that: (1) the Company hired a promoter - The DreamTeam Group -
to boost Galena's share price; (2) the promoter posted misleading
articles on Galena's behalf without properly disclosing its paid
marketing relationship; (3), Galena's stock price tripled in value from
$2 per share in July 2013 to almost $7.50 in the middle of January
during The DreamTeam Group's promotion; and (4) Galena insiders,
including its CEO sold Company stock during the time when the promoter's
positive articles on Galena were being published. The Company also
recently confirmed that the Securities Exchange Commission is
investigating these allegations. Galena stock closed at $3.08 per share
on March 19, 2014, down from its trailing year high of $7.77 per share.
If you currently own Galena common stock and are interested in
discussing your rights, or have information relating to this
investigation, please contact Kip B. Shuman or Rusty E. Glenn toll free
at (866) 974-8626 or email Mr. Shuman at firstname.lastname@example.org
or email Mr. Glenn at email@example.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in stockholder litigation.
[ Back To Technology News's Homepage ]